Understanding Ozempic and Gastroparesis: Who Should Be Monitored?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Exposure Analysis

If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be concerned about gastroparesis—a condition where the stomach empties slowly. Decades of pharmacovigilance have established that certain medications can affect gastrointestinal motility, and recent reports have focused on GLP-1 agonists like Ozempic. This page reviews current research on the association and outlines who may need closer monitoring.

Find Out If You Qualify for Compensation →

Bridging Legacy Health Knowledge and Specific Exposure Scenarios

The bridge from legacy health information to targeted exposure analysis involves recognizing that any pharmaceutical agent carries implications beyond its intended therapeutic window. For individuals in Virginia who have used Ozempic and subsequently developed gastroparesis-like symptoms, the legal and medical landscapes converge on questions of exposure duration, dosage history, and symptom onset timing. This transition demands careful consideration of how general health knowledge informs specific exposure scenarios, without overstepping into mechanistic claims about disease causation. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions.

Medical Evidence: Ozempic and Gastrointestinal Adverse Reactions

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, where a radiolabeled meal is tracked over time, with retention of more than 10% at 4 hours considered abnormal. The condition can significantly impair quality of life and nutritional status. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Risk Context: Inadequate Warnings and Legal Implications for Virginia Patients

While gastroparesis is not explicitly listed as an adverse reaction in these data, the drug’s known effect on gastric motility and the reported gastrointestinal symptoms suggest a mechanistic link. Delayed gastric emptying, a core feature of gastroparesis, is a known pharmacodynamic effect of GLP-1 receptor agonists. The reported symptoms—nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—overlap with those of gastroparesis, raising the possibility that Ozempic may induce or exacerbate this condition in susceptible individuals. The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration. The prescribing information for Ozempic includes warnings about serious hypersensitivity reactions, such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis. The label does note that gastrointestinal adverse reactions are common and that patients may discontinue treatment due to these reactions, but it does not explicitly inform patients or prescribers about the potential for gastroparesis as a distinct adverse effect. This gap in risk communication may affect patients’ ability to make informed decisions about treatment and to recognize early symptoms of gastroparesis. For Virginia patients who have developed gastroparesis after using Ozempic, attorney-related considerations include the statute of limitations for filing a product liability claim. In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For claims involving harm from a prescription drug, the timeline between exposure and documented harm is critical. Patients may not immediately associate their gastrointestinal symptoms with Ozempic, especially if symptoms develop gradually or are attributed to other causes. The onset of gastroparesis can be insidious, and diagnosis may require specialized testing. Therefore, the discovery rule may apply, meaning the statute of limitations begins when the patient knew or should have known that Ozempic caused their gastroparesis. This underscores the importance of timely medical evaluation and documentation. Patients should consult with a Virginia attorney experienced in pharmaceutical litigation to assess their specific circumstances, including the date of first use, the onset of symptoms, and the date of diagnosis. Legal counsel can help determine whether the statute of limitations has been met and whether the manufacturer’s warnings were adequate. Given the absence of a specific gastroparesis warning in the Ozempic label, affected patients may have grounds for a claim based on failure to warn.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Virginia?

In Virginia, the statute of limitations for personal injury claims is generally two years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Ozempic-related gastroparesis, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Ozempic caused their condition. It is crucial to seek legal advice promptly to ensure your claim is filed within the applicable time frame.

Does Ozempic have a warning about gastroparesis?

The prescribing information for Ozempic does not include a specific warning about gastroparesis. While it warns about serious hypersensitivity reactions and notes that gastrointestinal adverse reactions are common, it does not explicitly inform patients or prescribers about the potential for gastroparesis as a distinct adverse effect. This lack of specific warning may be relevant in failure-to-warn claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.